Literature DB >> 31245474

Biomaterial-engineering and neurobiological approaches for regenerating the injured cerebral cortex.

Itsuki Ajioka1,2.   

Abstract

The cerebral cortex is responsible for higher functions of the central nervous system (CNS), such as movement, sensation, and cognition. When the cerebral cortex is severely injured, these functions are irreversibly impaired. Although recent neurobiological studies reveal that the cortex has the potential for regeneration, therapies for functional recovery face some technological obstacles. Biomaterials have been used to evoke regenerative potential and promote regeneration in several tissues, including the CNS. This review presents a brief overview of new therapeutic strategies for cortical regeneration from the perspectives of neurobiology and biomaterial engineering, and discusses a promising technology for evoking the regenerative potential of the cerebral cortex.

Entities:  

Keywords:  Biomaterials; CNS, central nervous system; Cell cycle; Cerebral cortex; ES, embryonic stem; MSC, mesenchymal stem cell; MZ, marginal zone; NSC, neural stem cell; OB, olfactory bulb; Regeneration; VZ, ventricular zone; V–SVZ, ventricular–subventricular zone

Year:  2016        PMID: 31245474      PMCID: PMC6581816          DOI: 10.1016/j.reth.2016.02.002

Source DB:  PubMed          Journal:  Regen Ther        ISSN: 2352-3204            Impact factor:   3.651


Introduction

The cerebral cortex, one of the most highly evolved tissues in the body, is responsible for higher functions of the central nervous system (CNS), such as movement, sensation, and cognition. These higher functions are associated with complex but well-organized neuronal networks in the cerebral cortex, which is organized into layers and columns that receive inputs from and send outputs to the subcortical and other cortical areas. Over a century ago, neuroanatomists began investigating and describing the formation of the cerebral cortex. Ramón y Cajal, a pioneer in neuroanatomy research, believed that the regenerative property of the adult brain is extremely limited [1], and researchers since have assumed that the cerebral cortex and other CNS tissues do not regenerate after injury probably because of the following reasons. 1) Most of the neurons are generated from neuronal stem/progenitor cells during developmental stages except for the specific types of neurons generated from adult neural stem cells in the adult ventricular–subventricular zone (V–SVZ) of the lateral ventricle and the dentate gyrus of the hippocampus. 2) Many neural circuits are shaped during a critical period in early postnatal life and seem to largely lose plasticity after this period. Indeed, there are no clinically available therapies for regenerating the injured cerebral cortex. However, recent advances in neurobiology reveal that the cerebral cortex does have regenerative potential, and shed light on new therapeutic strategies for cortical regeneration. In this review, I will describe treatment strategies for regenerating the cerebral cortex after injury from the perspectives of neurobiology and biomaterial engineering, and identify technical limitations that these strategies must address.

Neurobiological approaches for cortical regeneration

Neural cell transplantation

During cortical development, cortical excitatory neurons and inhibitory neurons are generated from neural stem/progenitor cells in the cerebral cortex and the basal ganglia, respectively [2]. These immature neurons differentiate and form a 6-layered structure, based mostly on their network patterns. Excitatory neurons are generated from neural stem/progenitor cells in the cortical ventricular zone (VZ), which is quite far from the position where the neurons will eventually align and take their place in the cortical structure. Newly generated neurons migrate toward the brain surface, to the region beneath the marginal zone (MZ). Later-born neurons pass early-born neurons and reach their destination beneath the MZ first, to align at the upper layer. The upper-layer neurons extend their axons mainly into the intracortical area, while neurons in deeper layers extend mainly into the subcortical area. Cortical interneurons also align roughly according to their order of birth. Since specific gene-expression patterns contribute to generating different types of neurons [3], it is theoretically possible to manipulate neural stem/progenitor cells in vitro to obtain specific types of neurons. Although the developmental process of the cerebral cortex is more complex than that of the retina, the retina provides a good model for studying the fundamental processes of CNS development. Photoreceptor cells, a type of retinal neuron, can be generated from pluripotent stem cells [4], [5]. Since the degeneration of photoreceptor cells causes vision loss, transplanting photoreceptor cells into the retina is a promising strategy for retinal regeneration. Transplanted post-mitotic, immature photoreceptor cells integrate into the recipient retina more efficiently than do retinal progenitor cells [6]. When normal immature photoreceptor cells are transplanted into the Gnat1−/− mouse retina, in which photoreceptor cells degenerate, vision is recovered [7]. However, since there are no established techniques for generating specific types of cortical neurons, regenerative strategies for the cerebral cortex generally involve transplanting cortical progenitor cells rather than immature cortical neurons. When neural stem/progenitor cells are transplanted into the developing cortex, their progeny neurons align in the correct layer [8]; this is also the case when progenitor cells are transplanted into the injured cortex [9]. Although it is not presently possible to generate specific types of cortical neurons from pluripotent stem cells, it is possible to generate transplantable neural stem/progenitor cells [10], [11]. Transplanted neural stem/progenitor cells derived from human fetal brain tissue and induced pluripotent stem (iPS) cells can differentiate into neurons and survive in the ischemic brain [12], [13]. The use of multi-potent mesenchymal stem cells (MSCs) is another attractive strategy, since MSCs are easily isolated from bone marrow [14]. Transplanted MSCs can migrate and differentiate into neurons in the recipient cerebral cortex [15]. Functional recovery has been observed after transplanting embryonic cortical cells [16], neuronal cell line cells [17], neural stem/progenitor cells derived from iPS cells [18], or MSCs [19] into the injured cortex. However, it is not certain whether this functional recovery was caused by new neuronal networks of transplanted cells themselves or by the trophic factors secreted from transplanted cells, which enhances new neuronal networks of existing neurons in the recipient cortex. Thus, we must identify the factors that specifically contribute to functional recovery. For example, abrogating the transplanted cells after functional recovery will reveal whether recipient mice require ongoing support from these cells. Techniques for generating specific types of cortical neurons must also be established to obtain more effective transplantable cells.

Endogenous adult neural stem cells (NSCs)

The discovery of neural stem cells in the adult V–SVZ of the lateral ventricle and the dentate gyrus of the hippocampus made it possible to consider regenerative strategies using endogenous NSCs [20], [21], [22], [23]. In the normal adult, neuroblasts generated at the V–SVZ migrate into the olfactory bulb (OB), where they differentiate into mature neurons as part of the olfactory system [24]. When the cerebral cortex or striatum is injured, these neuroblasts migrate toward the injured area [25], [26], [27], [28], [29], [30]. Therapies using endogenous NSCs do not require cell transplantation and thus have advantages with respect to ethical issues and the immune response. However, some technical issues need to be resolved before endogenous NSCs can be used effectively to promote functional recovery. For instance, it is not clear whether these neuroblasts have the potential to differentiate into cortical neurons, or whether NSCs and neuroblasts can generate enough neurons to promote functional recovery. Since self-recovery is not sufficient for functional brain regeneration, the effective use of endogenous NSCs to regenerate the cerebral cortex will require a breakthrough technique, such as a method for expanding NSCs and neuroblasts in vivo.

Cell cycle

Neurons are believed to be post-mitotic and non-dividing because of a fundamental principle in developmental biology: cell differentiation and proliferation are mutually exclusive [31]. In general, when differentiated cells proliferate, they de-differentiate before advancing their cell cycle. Cell differentiation and proliferation are tightly coupled in neurons. Although neurons can advance their cell cycle in pathological situations such as ischemia and Alzheimer's disease, they undergo cell death after re-entering the cell cycle [32]. Techniques to uncouple proliferation from neuronal differentiation might contribute to alternative cortical regeneration therapies, and recent findings in cell-cycle mechanics and neurobiology suggest new strategies for developing such techniques. One cell becomes two cells after cell-cycle events such as DNA replication in the S phase and cell division in the M phase. The G1 and the G2 phases are gap phases that prepare the cell to advance into the S and the M phases, respectively. During the G1 phase, retinoblastoma protein (Rb) and its family members (p107 and p130) function as a brake to prevent the cell from entering the S phase [33], [34]. During G1 to S phase progression, cyclin D and cyclin-dependent kinase (Cdk) 4/6 complex phosphorylates Rb family members, which induce the dissociation of the Rb family from E2F transcriptional factors and the S phase-related gene to express. The loss of Rb in post-mitotic neurons induces cell-cycle reentry and causes cell death, probably because of the tight coupling of proliferation and neuronal differentiation [35]. Rb-family members also control the tight coupling of neuronal differentiation and proliferation in progenitor but not post-mitotic cells. In addition to directly regulating the transcription of cell-cycle-related genes, the Rb family regulates epigenetic modifications by associating with various epigenetic modifiers [31], [33]. In human retinoblastoma, RB1-mediated epigenetic regulation contributes to cancer progression [36]. During cancer progression, retinoblastoma cells co-express genes that are normally expressed in only one retinal-cell type [37]; thus, the loss of the Rb family in retinal progenitors can uncouple proliferation from neuronal differentiation by epigenetic dysregulation. Indeed, when neurons lose the tight coordination between cell-cycle exit and neuronal differentiation by the loss of the Rb family in progenitor cells, neurons can divide in some cases. For example, retinal progenitor cells lacking Rb-family members other than one p107 allele fully differentiate into horizontal interneurons [38]. However, p107-single (Rb; p107; p130) differentiated horizontal interneurons proliferate without de-differentiation and form tumors. In the mouse cerebral cortex, the loss of the Rb family or just Rb in progenitors causes immature neurons to divide [39], [40], [41]. However, the loss of the Rb family in post-mitotic neurons immediately after exiting the cell cycle does not cause cell division, even though the cells undergo S-phase progression [39]. Thus, once progenitor daughter cells exit their cell-cycle and initiate neuronal differentiation, they become tightly protected from undergoing cell division, and thereby maintain mitotic resistance even after acute Rb family inactivation. These findings lead us to speculate that neurons in the S phase may escape cell death and divide by overriding such mitotic safeguards. Importantly, in pathological situations, postmitotic neurons can advance their cell cycle, but then undergo cell death instead of cell division. For example, in pathological situations such as Alzheimer's disease (AD), Parkinson's disease (PD), and mouse stroke model, neurons advance their cell-cycle into the S phase and then undergo cell death [42], [43], [44], [45]. Since the inhibition of cell-cycle reentry by Cdk inhibitor prevents pathological neuron death [46], cell-cycle reentry contributes to disease progression. Moreover, Rb phosphorylation is correlated with the cell-cycle reentry of pathological neurons [47], [48] and the progression of AD [49], [50]. Thus, the safeguard against cell division may prevent neurons from entering the M phase but instead to lead cell death subsequent to S-phase progression. Since pathological neurons undergo cell death after re-entering the cell cycle, the transient inactivation of such mitotic safeguards and later the inactivation of Cdk to prevent multiple cell cycle reentry is an attractive regenerative strategy to replace dying neurons with new neurons.

Biomaterial-engineering approaches to cortical regeneration

Biomaterials without cell transplantation

Although recent neurobiological studies show that the injured CNS has the potential to regenerate, self-recovery is not sufficient for functional regeneration and recovery. Thus, biomaterials engineered to accelerate regeneration are an important strategy for functional recovery. Potential regenerative strategies using endogenous NSCs face a technical obstacle: the migrating neuroblasts cannot align in the cortical lesion because they do not pass through the glial-scar barrier formed by reactive astrocytes in response to brain injury. Since migrating neuroblasts generated from endogenous NSCs use blood vessels as a scaffold to move toward a brain lesion [51], [52], [53], blood-vessel-like biomaterials can be used as a scaffold to allow migrating neuroblasts to pass through the glial-scar barrier. We recently developed a laminin-rich sponge material for the three-dimensional (3D) proliferation culture of p107-single horizontal interneurons [54]. Since laminin is a primary component of the extracellular matrix in the basement membrane on the surface of blood vessels, we transplanted the laminin-rich sponge material into the injured cerebral cortex [55]. As expected, neuroblasts migrated into the cortical lesion along the laminin-rich sponge material. Thus, blood-vessel-like biomaterials can support neuroblast migration, which is important for cortical regeneration. Other transplanted biomaterials are reported to enhance the regenerative process [56], [57], [58]. Furthermore, engineered biomaterials that release a bioactive factor to promote the formation of new blood vessels may promote neuronal migration and survival, and biomaterials that release a bioactive factor to enhance neuronal maturation may enhance neuronal connections to other areas of the brain.

Biomaterials with cell transplantation

Biomaterials were originally defined as nonviable materials designed to interact with biological systems when used in medical devices [59]. However, biomaterials now include transplantable hybrids containing both nonviable materials and living cells [60]. A combination of neural stem/progenitor cell transplantation and biomaterials can enhance the regenerative process and promote functional cortical recovery in some cases [61], [62], [63], [64]. Again, to develop reliable regenerative therapies for functional recovery, we must determine which factors are essential during the regenerative process.

Future perspectives

In the past few years, remarkable advances have been made in culturing 3D organoids from pluripotent stem cells—retinal organoids, for example [65]. This technology has great potential not only for determining the potency of pluripotent stem cells to generate self-organizing neural tissue, but also for retinal regeneration therapy. Transplants of 3D retinal organoids derived from pluripotent stem cells promote retinal regeneration in mice, even when advanced degeneration is present [66]. Cerebral organoids have also been generated from pluripotent stem cells [67], [68], and the potential use of these organoids for regenerating the injured cerebral cortex merits further study. Recent advances in neurobiology and in biomaterial engineering shed new light on the potential of cortical regeneration, and researchers have tried various methods to promote regeneration (see Fig. 1). Although functional recovery has occurred after neural stem/progenitor cell transplantation, careful analysis is required to understand how neuronal networks regenerate. There is no doubt that the cerebral cortex has the potential to regenerate after injury. Future studies combining neurobiology and biomaterial engineering will drive the development of therapeutic strategies to regenerate the injured cerebral cortex.
Fig. 1. Neurobiological and biomaterial-engineering approaches for regenerating the injured cerebral cortex Injured neurons are replaced by 1) neural cell transplantation, 2) endogenous neuroblast migration and proliferation, and/or 3) endogenous neuron proliferation. Transplanted biomaterials, either with or without living cells, can accelerate cortical regeneration.
  63 in total

1.  Subventricular zone astrocytes are neural stem cells in the adult mammalian brain.

Authors:  F Doetsch; I Caillé; D A Lim; J M García-Verdugo; A Alvarez-Buylla
Journal:  Cell       Date:  1999-06-11       Impact factor: 41.582

2.  Subventricular zone-derived neuroblasts migrate and differentiate into mature neurons in the post-stroke adult striatum.

Authors:  Toru Yamashita; Mikiko Ninomiya; Pilar Hernández Acosta; Jose Manuel García-Verdugo; Takehiko Sunabori; Masanori Sakaguchi; Kazuhide Adachi; Takuro Kojima; Yuki Hirota; Takeshi Kawase; Nobuo Araki; Koji Abe; Hideyuki Okano; Kazunobu Sawamoto
Journal:  J Neurosci       Date:  2006-06-14       Impact factor: 6.167

3.  Self-organizing optic-cup morphogenesis in three-dimensional culture.

Authors:  Mototsugu Eiraku; Nozomu Takata; Hiroki Ishibashi; Masako Kawada; Eriko Sakakura; Satoru Okuda; Kiyotoshi Sekiguchi; Taiji Adachi; Yoshiki Sasai
Journal:  Nature       Date:  2011-04-07       Impact factor: 49.962

4.  Long-distance neuronal migration in the adult mammalian brain.

Authors:  C Lois; A Alvarez-Buylla
Journal:  Science       Date:  1994-05-20       Impact factor: 47.728

5.  Neural progenitors from human embryonic stem cells.

Authors:  B E Reubinoff; P Itsykson; T Turetsky; M F Pera; E Reinhartz; A Itzik; T Ben-Hur
Journal:  Nat Biotechnol       Date:  2001-12       Impact factor: 54.908

6.  Coexpression of normally incompatible developmental pathways in retinoblastoma genesis.

Authors:  Justina McEvoy; Jacqueline Flores-Otero; Jiakun Zhang; Katie Nemeth; Rachel Brennan; Cori Bradley; Fred Krafcik; Carlos Rodriguez-Galindo; Matthew Wilson; Shunbin Xiong; Guillermina Lozano; Julien Sage; Ligia Fu; Lotfi Louhibi; Jeff Trimarchi; Amar Pani; Richard Smeyne; Dianna Johnson; Michael A Dyer
Journal:  Cancer Cell       Date:  2011-08-16       Impact factor: 31.743

7.  Hypoxia-ischemia induces DNA synthesis without cell proliferation in dying neurons in adult rodent brain.

Authors:  Chia-Yi Kuan; Aryn J Schloemer; Aigang Lu; Kevin A Burns; Wei-Lan Weng; Michael T Williams; Kenneth I Strauss; Charles V Vorhees; Richard A Flavell; Roger J Davis; Frank R Sharp; Pasko Rakic
Journal:  J Neurosci       Date:  2004-11-24       Impact factor: 6.167

8.  Cyclin-dependent kinases as a therapeutic target for stroke.

Authors:  H Osuga; S Osuga; F Wang; R Fetni; M J Hogan; R S Slack; A M Hakim; J E Ikeda; D S Park
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

9.  Transplantation of human neural precursor cells in Matrigel scaffolding improves outcome from focal cerebral ischemia after delayed postischemic treatment in rats.

Authors:  Kunlin Jin; Xiaoou Mao; Lin Xie; Veronica Galvan; Bin Lai; Yaoming Wang; Olivia Gorostiza; Xiaomei Wang; David A Greenberg
Journal:  J Cereb Blood Flow Metab       Date:  2009-10-14       Impact factor: 6.200

10.  Cerebral organoids model human brain development and microcephaly.

Authors:  Madeline A Lancaster; Magdalena Renner; Carol-Anne Martin; Daniel Wenzel; Louise S Bicknell; Matthew E Hurles; Tessa Homfray; Josef M Penninger; Andrew P Jackson; Juergen A Knoblich
Journal:  Nature       Date:  2013-08-28       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.